Related Experiment Videos
[Clinical studies of panipenem/betamipron in pediatrics]
Insights
Panipenem/betamipron (PAPM/BP), a new parenteral carbapenem antibiotic, showed high efficacy in treating pediatric bacterial infections. This promising antibiotic demonstrated a 92% clinical efficacy rate with no observed adverse reactions in children.
Area of Science:
- Pediatric infectious diseases
- Clinical pharmacology
- Antibiotic therapy
Background:
- Parenteral carbapenem antibiotics are crucial for treating severe bacterial infections.
- Panipenem/betamipron (PAPM/BP) is a novel parenteral carbapenem antibiotic.
- Evaluating its pediatric application is essential.
Purpose of the Study:
- To assess the clinical efficacy and safety of panipenem/betamipron (PAPM/BP) in pediatric patients.
- To determine the effectiveness of PAPM/BP in various pediatric infections.
Main Methods:
- A clinical study involving 13 pediatric patients with diverse bacterial infections.
- Administration of PAPM/BP via intravenous drip infusion.
- Dosage ranged from 12-27 mg/kg/day, given three or four times daily for 4-25 days.
Main Results:
- Achieved an overall clinical efficacy rate of 92% (3 excellent, 9 good).
- No adverse reactions were reported in any of the pediatric patients.
- Minor laboratory abnormalities (elevated GOT, GPT, urobilinogen) were noted in 3 cases.
Conclusions:
- Panipenem/betamipron (PAPM/BP) is a safe and effective antibiotic for treating bacterial infections in children.
- PAPM/BP demonstrates significant promise as a therapeutic option in pediatric infectious disease management.
Abstract:
We conducted clinical studies on panipenem/betamipron (PAPM/BP), a newly developed parenteral carbapenem antibiotic, for its clinical application in the field of pediatrics. 1. A clinical study was performed on 13 children with infections, including 6 with acute bronchopneumonia, 1 each with acute pharyngitis, acute bronchitis, sepsis, staphylococcal scalded skin syndrome, urinary tract infection, subcutaneous abscess and furuncle. PAPM/BP was administered by intravenous drip infusion. Doses varied from 12 to 27 mg/kg body weight were given t.i.d. or q.i.d. Lengths of treatment ranged from 4 to 25 days. Clinical efficacies were excellent in 3 and good in 9 cases, with an efficacy rate of 92%. 2. No adverse reactions were observed. In laboratory tests, elevations of GOT, GPT and urobilinogen were observed in 3 cases. It was concluded that PAPM/BP was a promising drug for the treatment of bacterial infections in children.